Abstract
Objectives To study the geographic patterns, temporal trends, and predictors of one-day discharge following radical prostatectomy.
Methods We conducted a retrospective cohort study of men diagnosed with prostate cancer from 2008 to 2019 in the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database. Patients with metastatic disease, health maintenance organization coverage, or age younger than 66 years were excluded. Type of surgery and length of stay were derived from inpatient claims. We compared one-day discharge by early (2008–2013) and late (2014–2019) periods, by census region, and by individual- and facility-level factors, and used generalized estimating equations to estimate adjusted odds ratios (aOR) with 95% confidence intervals (CI), accounting for clustering of patients within hospitals.
Results Among 40,728 patients treated at 1,048 hospitals, 52.4% were discharged on postoperative day 1, increasing from 48.8% (2008–2013) to 56.8% (2014–2019). Higher odds of one-day discharge were associated with robotic surgery (aOR 2.88, 95% CI 2.54–3.27) and treatment at a National Cancer Institute-designated comprehensive cancer center (aOR 1.88, 95% CI 1.28–2.76). Black versus White patients (aOR 0.76, 95% CI 0.70–0.82), unmarried versus married patients (aOR 0.79, 95% CI 0.73–0.85), and patients in the lowest versus highest neighborhood socioeconomic quintile (aOR 0.86, 95% CI 0.79–0.94) had lower odds. Odds were 31% higher in the late versus early period (aOR 1.31, 95% CI 1.20–1.43). Regional differences were attenuated in sensitivity analyses.
Conclusions One-day discharge after radical prostatectomy has increased over time and is now the predominant practice among Medicare beneficiaries, driven primarily by robotic surgery and treatment era. Persistent racial and socioeconomic differences in discharge patterns warrant further research into whether early discharge is equally safe and beneficial across patient populations.
Competing Interest Statement
The authors have declared no competing interest.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Rutgers University Institutional Review Board, Study ID Pro2021001673. Informed consent was waived because the study analyzed de-identified secondary data (SEER-Medicare linked database) under a National Cancer Institute data use agreement.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data underlying this study are third-party data from the SEER-Medicare linked database, obtained from the U.S. National Cancer Institute (NCI) under a data use agreement. The authors are not permitted to share these data publicly because they contain protected health information governed by NCI and the Centers for Medicare & Medicaid Services. Other researchers may request access to identical SEER-Medicare data through the NCI Healthcare Delivery Research Program (https://healthcaredelivery.cancer.gov/seermedicare/obtain/), subject to approval of a data request and execution of a data use agreement. The authors did not have any special access privileges that others would not have. SAS code used for cohort construction and analysis is available from the corresponding author on request.





